In a recently published study, researchers sought to determine the cost effectiveness of bevacizumab in treating recurrent ovarian cancer from a Canadian public payer perspective.
Ovarian cancer is a leading cause of cancer-related morality, and in Canada, ovarian cancer is estimated to affect approximately 1 in every 71 women. The prognosis for ovarian cancer is poor, and very few therapeutic options are available for women with recurrent ovarian cancer, especially disease that is platinum-resistant.
In a recently published study, researchers sought to determine the cost effectiveness of bevacizumab in treating recurrent ovarian cancer from a Canadian public payer perspective. The investigators compared bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant recurrent ovarian cancer based on clinical data from the AURELLIA phase 3 trial.
The study was conducted by evaluating a 3 health-state cohort-based partitioned survival models developed to assess the cost utility of bevacizumab plus chemotherapy versus chemotherapy alone over a 7-year horizon. Researchers reconstructed individual patient data from published Kaplan-Meier curves. Clinical parameters, including progression-free survival and overall survival, were derived from the AURELIA trial. Costs, resource utilization, and utility values from recent Canadian sources were compiled by the study authors and used to populate the model. The results of the study were then presented in incremental cost-utility ratios (ICURs).
In reconstructing the individual patient data, the authors found:
Overall, researchers found that the addition of bevacizumab to a single-agent chemotherapy treatment, although it improved patient outcomes, is unlikely to be cost-effective in this patient population. This result is due to bevacizumab plus chemotherapy not being considered cost-effective at willingness-to-pay thresholds below approximately $200,000 (approximately $155,900 USD) per QALY gained. However, the study’s authors also note that these results provide some preliminary validation for the use of individual patient data-reconstruction techniques in pharmacoeconomic evaluation.
Reference
Ball G, Xie F, Tarride JE. Economic evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada. Published online May 29, 2017. Pharmacoeconomics. doi: 10.1007/s41669-017-0030-7.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.